TMEM158-mediated TGF-β signaling pathway modulates the sensitivity of TP53-deficient osteosarcoma to USP14 inhibitors

Key Points

• Sensitivity to USP14 inhibitors increases with altered TGF-β signaling modulation.
• TP53-deficient osteosarcoma shows a notable response to these treatments, indicating vulnerability.
• The analysis involves assessing the role of TMEM158 in TGF-β signaling pathways.
• This suggests new therapeutic avenues for osteosarcoma management, particularly in specific genetic contexts.